Skip to main content

Luis Paz-Ares

Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre (University Hospital October 12), Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), all in Madrid, Spain. He is also a board member of CiberONC (National Network of Cancer Research), and an active member of cooperative groups (EORTC, ETOP; SLCG, SOGUG) and scientific societies (ASCO, ESMO, IASLC, SEOM, ASEICA - Elect President).

He graduated with a degree in medicine from the Universidad Autonoma de Madrid in 1986, and completed a PhD in 1993 at the same university. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Scotland (1993–1995), and completed a master's degree in Clinical Pharmacology at the University of Glasgow in 1995. Luis Paz-Ares also completed a master's degree in Clinical Unit Management at the UNED-Fundación Universidad Empresa (2002–2003).

Prior to his current position, he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit, and responsible for early clinical studies of thoracic and genitourinary tumors at the University Hospital October 12 in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts, USA (1999–2000).

Luis Paz-Ares's research focuses on lung cancer and the development of new therapeutic strategies both in the lab and the clinic, and he has published more than 300 articles in peer-reviewed journals including The New England Journal of Medicine, The Lancet, The Lancet Oncology, Journal of Clinical Oncology, and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, the European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices, and the European Medicines Agency. Research sexenia: 6, last one: June 2020.